Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06112379
Title A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS

No variant requirements are available.